Relmada Therapeutics

Relmada Therapeutics (Nasdaq: $RLMD) is a clinical-stage biotechnology company developing novel therapies for CNS diseases and bladder cancer.

[Relmada Therapeutics @relmada]

June marked continued progress across Relmada’s oncology and CNS pipeline programs.

We remain focused on advancing innovative therapies for patients with signifi cant unmet medical needs.

https://t.co/oRsiDb4uHS

#Biotech #Oncology #CNS $RLMD

[Relmada Therapeutics @relmada]

Relmada Therapeutics has joined the Russell 2000® and Russell 3000® Indexes, marking a meaningful accomplishment for the company as we continue advancing ongoing progress, including robust data for NDV-01 in NMIBC.

Learn more: https://t.co/tV37YtD6wz

$RLMD @FTSERussell

[Relmada Therapeutics @relmada]

Relmada continues advancing its pipeline with upcoming development milestones expected in 2026.

Stay updated: https://t.co/hwIYB9VZAM $RLMD

[Relmada Therapeutics @relmada]

Beyond oncology, Relmada is advancing sepranolone, a novel candidate being evaluated for compulsive behaviors through modulation of GABAₐ receptor activity.

Learn more about our CNS pipeline: https://t.co/fPOZnUbRdu $RLMD

[Relmada Therapeutics @relmada]

Focused on innovation. Driven by patients.

Relmada Therapeutics is committed to advancing therapies for oncology and CNS disorders with signifi cant unmet need.

https://t.co/oRsiDb4uHS

#Biotech #HealthcareInnovation $RLMD

[Relmada Therapeutics @relmada]

NDV-01 is administered as a ready-to-use sustained-release Gem/Doce formulation administered in under 5 minutes.

Learn more about the program: https://t.co/HQfYZCe9Ah $RLMD

[Relmada Therapeutics @relmada]

Did you know non-muscle invasive bladder cancer (NMIBC) represents approximately 75–80% of newly diagnosed bladder cancer cases?
Relmada is focused on advancing therapies designed to address ongoing treatment challenges in NMIBC.

Learn more: https://t.co/HQfYZCe9Ah $RLMD

[Relmada Therapeutics @relmada]

We're pleased to welcome Michael Quirk, PhD, as Senior Advisor for Relmada's Sepranolone Program. His CNS expertise will help advance sepranolone, Relmada’s GABAA receptor modulator for Prader-Willi syndrome and CNS disorders.

Read more: https://t.co/v2WwdAfBDM $RLMD

[Relmada Therapeutics @relmada]

Advancing innovation in NMIBC.

NDV-01 is designed to support prolonged bladder exposure and streamlined in-offi ce administration for patients with non-muscle invasive bladder cancer.

Learn more about our pipeline: https://t.co/fPOZnUbRdu $RLMD

[Relmada Therapeutics @relmada]

NDV-01 is designed to support sustained drug exposure within the bladder through a novel formulation approach.

Learn more: https://t.co/oRsiDb4uHS $RLMD

[Relmada Therapeutics @relmada]

Clinical development is guided by data, consistency, and a focus on advancing meaningful treatment options.

Learn more: https://t.co/oRsiDb4uHS $RLMD

[Relmada Therapeutics @relmada]

Relmada Therapeutics will participate in the @Jefferies Global Healthcare Conference, June 2-4, 2026 in New York. CEO Sergio Traversa and CFO Maged Shenouda will speak in a fireside chat on June 4, 2026 at 12:50 PM ET. Details: https://t.co/aVvDCce4Vi $RLMD #JefferiesHealthcare

[Relmada Therapeutics @relmada]

Sustained local drug exposure continues to be a key focus in advancing therapies for non-muscle invasive bladder cancer.

Innovative approaches designed to maintain therapeutic presence in the bladder may help address persistent treatment challenges. https://t.co/oRsiDb4uHS $RLMD

[Relmada Therapeutics @relmada]

Efficient administration remains an important consideration in oncology care, notably in settings where repeated treatments may be required.

NDV-01 is designed with a streamlined delivery process that may support ease of use in clinical practice. https://t.co/oRsiDb4uHS $RLMD

[Relmada Therapeutics @relmada]

Bladder cancer presents unique challenges in how therapies are delivered and retained within the bladder environment.

Learn more: https://t.co/oRsiDb4uHS $RLMD

[Relmada Therapeutics @relmada]

Advancing therapies in oncology requires precision across formulation, delivery, and clinical development.

Learn more: https://t.co/oRsiDb4uHS $RLMD

[Relmada Therapeutics @relmada]

Today at #AUA26: Relmada presents an oral Trial-in-Progress session for REL-NDV01-301, the Phase 3 NDV-01 study in intermediate-risk NMIBC.

📍 Hall B/The Square/Learning Lab
🕘 9:56–10:04 AM ET

Read more: https://t.co/X4GpAmqqmt $RLMD

[Relmada Therapeutics @relmada]

Today at #AUA26: Relmada presents NDV-01 Phase 2 poster IP02-03 in high-risk NMIBC.

📍 Room 146A, Walter E. Washington Convention Center
🕖 7:00–9:00 AM ET

Details: https://t.co/X4GpAmqqmt $RLMD

[Relmada Therapeutics @relmada]

Reminder: NDV-01 will be featured this week at #AUA26 as Relmada advances the program across multiple NMIBC settings, including its Phase 3 registrational study expected to begin mid-2026.

📌 May 15, 7–9 AM ET
📌 May 17, 9:56–10:04 AM ET

Details: https://t.co/X4GpAmqqmt $RLMD

[Relmada Therapeutics @relmada]

Relmada Therapeutics reports first quarter 2026 financial results and provides business update.

Read more: https://t.co/sh21rXeKTN $RLMD